Abatacept (CTLA4-Ig)

Screening: finding T1D before it strikes

Any prevention therapy only helps if at-risk people are found early, and that depends on screening. Type 1 diabetes (T1D) develops along a defined three-stage path. Stage 1 is two or more islet autoantibodies (against insulin, GAD, IA-2, or ZnT8) with normal blood glucose and no symptoms; stage 2 adds abnormal glucose but still no symptoms; stage 3 is clinical disease, when insulin is needed.¹ The autoantibodies are powerful predictors: once a child has two or more, lifetime progression to clinical diabetes approaches near-certainty, so multiple-antibody individuals are considered to already have early-stage disease rather than merely "risk."²

Screening is often offered to relatives of people with T1D, but roughly 90% of new cases have no family history — so finding most at-risk people requires general-population autoantibody (and sometimes genetic-risk) testing.² Early detection is valuable even without treatment: monitored individuals are far less likely to arrive in diabetic ketoacidosis (DKA), a dangerous and sometimes fatal emergency, when they reach stage 3.³ International JDRF/ADA consensus guidance now sets out how to monitor antibody-positive people and when to offer trials or approved therapy.³

Therapy: a borrowed arthritis drug, tested upstream

Abatacept (CTLA4-Ig, sold as Orencia by Bristol Myers Squibb) is a fusion protein that blocks the co-stimulation signal T cells need to switch on: it binds CD80/CD86 on antigen-presenting cells, preventing CD28 engagement, so autoreactive T cells are dampened rather than the whole immune system suppressed.⁴ It is approved for rheumatoid and juvenile arthritis and graft-versus-host disease — not for diabetes — making this a repurposing story.⁵

New-onset (stage 3) T1D. In a TrialNet phase-2 trial (NCT00505375), 112 people aged 6-45 diagnosed within 100 days received 27 monthly IV infusions of abatacept or placebo over 2 years. Insulin-production (C-peptide) was 59% higher with abatacept at 2 years (P=0.0029), equal to an estimated 9.6-month delay in beta-cell decline.⁴ Tellingly, after about 6 months the decline ran parallel to placebo — a one-time lag, not an ongoing rescue.⁴ One year after stopping, the ~9.5-month gap and lower HbA1c persisted (3 years from diagnosis).⁶

Stage 1 prevention. The pivotal upstream test (NCT01773707) randomized 212 antibody-positive relatives aged 6-45 with normal glucose to 12 months of abatacept or placebo. It missed its primary endpoint: progression to abnormal glucose tolerance or diabetes was not significantly reduced (hazard ratio 0.70; 95% CI 0.45-1.09; P=0.11), though C-peptide was modestly preserved and immune cell subsets shifted during treatment.⁷ So in the earliest, healthiest stage, abatacept did not prove it can delay onset.⁷

Safety. Across 2 years it was well tolerated — few infusion reactions and no excess infection or neutropenia — which matters when treating people who currently feel healthy; live vaccines, however, must be avoided around dosing.⁴

Access. Because no T1D indication exists, any use is investigational or off-label; there is no prevention pathway, no T1D label, and no diabetes-specific pricing.⁵

What's coming

Abatacept's clearest future is combination and sequencing, not solo prevention. Its early, fading effect mirrors other single agents, and researchers now frame it as a candidate to pair with complementary therapies or to deploy at the stage where T-cell activation is highest, rather than in the quietest stage-1 window.⁴ A subcutaneous formulation has also been floated to ease delivery in future trials.⁴ For now it remains a proof of mechanism — co-stimulation blockade can bend the curve — awaiting a smarter regimen.

References

1. Sims EK, et al. Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. Diabetes (2022). https://doi.org/10.2337/dbi20-0054 ↩

2. Sims EK, et al. Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. Diabetes (2022). https://doi.org/10.2337/dbi20-0054 ↩ ↩²

3. Phillip M, et al. Consensus Guidance for Monitoring Individuals With Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes. Diabetes Care (2024). https://doi.org/10.2337/dci24-0042 ↩ ↩²

4. Orban T, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet (2011). https://doi.org/10.1016/S0140-6736%2811%2960886-6 ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

5. Orencia (abatacept) FDA Approval History. Drugs.com (accessed 2026). https://www.drugs.com/history/orencia.html ↩ ↩²

6. Orban T, et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care (2014). https://doi.org/10.2337/dc13-0604 ↩

7. Russell WE, et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care (2023). https://doi.org/10.2337/dc22-2200 ↩ ↩²